Methodology

This tracker reconstructs the active US gastroenterology MSO private equity field from primary filings, regulatory consent orders, sponsor portfolio pages, professional society advocacy memoranda, and named trade press transaction reports. Every numeric or dated claim carries an inline source URL pointing to the canonical document. Where the open record is ambiguous, partial, or contradicted by widely repeated trade press summaries, we flag the cell as GAP rather than smooth the answer.

Three reference frames anchor the work. The first is the SEC and 8-K filing trail for public-strategic acquirers, principally Cardinal Health (NYSE: CAH) Q2 FY2025 8-K for GI Alliance and the UnitedHealth Group segment disclosures touching SCA Health for US Digestive Health. The second is the FTC public docket: the Welsh Carson Anderson and Stowe matter file, the Federal Register consent analysis published February 18, 2025, and the April 2026 USAP settlement-in-principle release. The third is the CMS rulebook: the CY2026 MPFS final rule (CMS-1832-F) published November 5, 2025, the CMS MM14315 summary, and the ACG, AGA, and ASGE joint comment letter dated September 16, 2025.

Each platform row carries a per-cell confidence rating. HIGH cells are corroborated by at least two independent primary sources, including SEC filings, press releases issued by the buyer, or court or agency dockets. MEDIUM cells rest on sponsor portfolio pages or trade press summaries that we could not cross-check against a regulatory or filed document. LOW cells are reported once in trade press without corroboration. GAP cells flag the absence of a confirmable cap-table or transaction record. We refuse to fill GAPs with inference.

Transaction values reflect closing announcements where disclosed; where the buyer is public and the disclosed metric is enterprise value, we cite that figure and separately note implied equity value where the brief permits. Multiples are reported as ranges keyed to the named source. We do not blend disparate methodologies into a single number.

The MSO category itself is a defined term in this tracker. A management services organization owns the non-clinical operating infrastructure (real estate, billing, payor contracting, IT, compliance, ancillary lines including ASC partial ownership, pathology, infusion, anesthesia coordination, and supply chain procurement) and contracts with a physician-owned professional corporation through a Management Services Agreement. The MSO does not own the clinical practice or directly employ physicians providing medical care. The economic interest flows through the MSA fee structure plus equity interest in the ancillary businesses where state law permits non-physician ownership (notably ASCs, where the physician-investor partnership remains the dominant structure but non-physician corporate participation is permissible under state ASC licensing regimes). Throughout this tracker the “platform” refers to the combined MSO plus affiliated PC plus ancillary businesses operating under common branding and shared management. We use “sponsor” to mean the controlling equity holder of the MSO, whether a PE fund, a strategic acquirer, or a pension plan investor such as OMERS.

We exclude pure clinical research organizations, technology-only GPO platforms (with the Specialty Networks GPO carve-out noted because it functions as direct infrastructure for Cardinal Health’s GI Alliance acquisition), payor risk-adjustment vendors (notably Vatica Health, persistently miscategorized as a GI MSO), and non-clinical practice management software vendors. We include hybrid platforms (PE GI Solutions, Capital Digestive Care) where the platform combines MSO and ASC management functions even where the formal cap-table separates the practice and the management entity.

The reporting cutoff for closed transactions is June 16, 2026. Pending or rumored transactions not confirmed by a buyer press release, SEC filing, or named investment-bank engagement disclosure are excluded. Where trade press reports a transaction without buyer or seller confirmation, we treat the report as a MEDIUM signal pending corroboration. The user should expect future revisions as the Cardinal Health FY2026 10-K, the UnitedHealth Group Optum Health segment disclosures, and any FY2027 sponsor portfolio disclosures land.

Macro spine: workforce, screening volume, and demographic tailwind

The American College of Gastroenterology represents more than 20,000 clinical members across more than 86 countries as of 2025 and operates the principal payment-policy voice for community GI through its Practice Management Committee and political action committee (ACG via Newswise; ACG analysis of CY2026 MPFS, November 4, 2025). The American Gastroenterological Association reports more than 16,000 professional members worldwide (AGA membership page).

The active US gastroenterologist workforce is 18,756 specialists, comprising 17,147 adult specialists and 1,609 pediatric specialists (Gastro Scholar comprehensive statistics 2025). The Bureau of Labor Statistics May 2024 Occupational Employment and Wage Statistics survey lists gastroenterologist median total compensation at $236,350 (BLS OEWS May 2024; SalaryDr derived from BLS).

The 2024 Medicus Healthcare Solutions white paper projects a deficit of 1,630 full-time gastroenterologists by 2025 against demand of 17,170 and supply of 15,540 (Medicus white paper). More than 50 percent of practicing GIs are age 55 or older. Approximately 600 new fellows enter the workforce annually against roughly 1,000 retiring or scaling back, producing a net deficit near 400 GIs per year. For the 2025 appointment year, the National Resident Matching Program placed 12,390 fellowship trainees across 77 subspecialties against 14,620 offered positions (NRMP 2025 results; AGA fellowship match). In the 2025 GI Match specifically, 99.6 percent of available positions filled, yet 35 percent of qualified applicants did not match due to constrained spots (Gastro Scholar 2025).

The demographic tailwind is structural. The US population age 65 and older grew 3.1 percent to 61.2 million between 2023 and 2024, accounting for 18.0 percent of the total population, up from 12.4 percent in 2004 (US Census Bureau, June 2025). By 2030, 71.6 million Americans will be 65 or older (Population Reference Bureau fact sheet). Roughly 40 percent of patients seeking GI care are over age 60, making the senior segment the primary volume driver (Gastro Scholar 2025).

Annual colonoscopy volume exceeds 15 million procedures in the United States (iData Research). The three named volume drivers are the pandemic backlog, the USPSTF expansion to age 45 for average-risk screening, and the aging Boomer cohort (ColoWrap volume analysis). The hospital outpatient department share of the total ambulatory surgery market has dropped from nearly 60 percent to 40 percent over the past 15 years as procedures have migrated to ambulatory surgery centers (OR Manager). Medicare pays approximately 53 percent of the HOPD rate when the same procedure is performed in an ASC (HFMA payment differences). The MedPAC March 2025 report to Congress provides the current ASC status update (MedPAC March 2025, Chapter 10).

The screening universe expanded in 2021 when the US Preventive Services Task Force lowered the recommended starting age for colorectal cancer screening from 50 to 45 (USPSTF final recommendation; USPSTF screening recommendation page). The task force assigns Grade B certainty for ages 45 to 49 and Grade A for ages 50 to 75, with selective screening for ages 76 to 85 (USPSTF clinician summary). Under the Affordable Care Act, private health plans must cover screening colonoscopy with no out-of-pocket cost starting at age 45 for policy years beginning on or after May 31, 2022 (American Cancer Society coverage explainer; FacingOurRisk coverage memo).

The American Cancer Society estimated 152,810 new colorectal cancer cases in 2024 (Colorectal Cancer Alliance summarizing ACS) and 154,270 in 2025 (107,320 colon plus 46,950 rectal) with 52,900 projected deaths (Siegel et al., Cancer Statistics 2025; ACS Cancer Facts and Figures 2024). Incidence among adults under 55 continues to rise 1 to 2 percent annually, and colorectal cancer is now the leading cause of cancer death in men under 50 and the second leading cause in women under 50 (ACS key statistics).

The IBD prevalence base is wider than most platform pitch decks acknowledge. More than three million US adults live with Crohn’s disease or ulcerative colitis (1.2 million men, 1.9 million women), with total IBD diagnosed in more than 0.7 percent of Americans, or 721 cases per 100,000 (Crohn’s and Colitis Foundation groundbreaking study). Metabolic dysfunction associated steatotic liver disease, formerly nonalcoholic fatty liver disease, is the most prevalent liver disease in the country, with an estimated 38 percent of US adults and 7 to 14 percent of children affected (Diabetes Care). Approximately half of MASLD patients have the more progressive MASH form, and one in five have advanced liver fibrosis (American Liver Foundation). MASLD prevalence is projected to exceed 55 percent of US adults by 2040 (PMC, emerging therapies and real-world MASLD application).

The Cardinal Health and GI Alliance close (January 30, 2025): the structural watershed

The single most important transaction in the 2024 to 2026 US gastroenterology MSO cycle is Cardinal Health’s January 30, 2025 acquisition of a 73 percent majority stake in GI Alliance for approximately $2.8 billion, with implied total transaction enterprise value near $3.9 billion (Cardinal Health November 11, 2024 announcement; PR Newswire mirror; Cardinal Health 8-K Q2 FY2025; Healthcare Finance News; Mergerlinks summary). Apollo Hybrid Value funds exited fully at close.

The mechanics are public. In November 2024, Cardinal Health announced agreement to acquire a 71 percent majority stake; the deal closed January 30, 2025 at a final 73 percent stake, with shares purchased from a combination of GI Alliance physician owners and Apollo funds. Cardinal Health holds a call right beginning year three to acquire up to 100 percent of the remaining minority equity (Cardinal Health 8-K Q2 FY2025). The transaction converts GI Alliance into a Pharmaceutical and Specialty Solutions segment platform, layered with the group purchasing organization infrastructure already acquired via Specialty Networks in March 2024 (Becker’s Physician Leadership).

The Apollo position originated in the August 2022 physician-led recapitalization at a $2.2 billion enterprise value (Apollo press release; Latham and Watkins; Waud Capital exit announcement). Apollo’s investment was structured by its Hybrid Value strategy as a non-control minority position alongside a physician-led buyout that left physician owners holding approximately 70 percent of equity. Waud Capital, the original 2018 sponsor, exited at the August 2022 close.

For next-buyer math, the watershed is that Cardinal Health is a public strategic, not a Hybrid Value PE sponsor. The hold horizon is indefinite. The cost of capital is materially lower than a typical 7-to-10-year PE fund. The governance overhead is public-company standard, with quarterly disclosure cycles tied to NYSE reporting. The acquisition rationale, as articulated by Cardinal Health management, is to attach a clinical MSO to the Specialty Networks data spine, then expand across adjacent specialties. GI Alliance acquired Urology America on April 30, 2025 as the first non-GI specialty add-on under the Cardinal Health roof (CB Insights GI Alliance financials).

The implication for sellers and competing platform CEOs is that GI Alliance now bids against incoming targets with strategic-buyer economics rather than fund-life economics. The next-buyer math at a typical mid-market regional GI add-on, historically dominated by PE platform roll-up cost-of-capital, now competes against a public strategic with permanent capital and a 27,000-employee distribution backbone. This is the structural shift of the 2024 to 2026 cycle.

The mechanics of the Cardinal Health and GI Alliance combination repay close reading by anyone modeling GI MSO valuations going forward. The acquisition does three operationally distinct things at once. First, it converts a 2018-vintage clinical roll-up into a segment of a public pharmacy and medical distribution business with NYSE-mandated quarterly disclosure, sharply reducing the information asymmetry that historically protected PE-backed platform pricing. Second, it bolts the clinical MSO onto the Specialty Networks PPS Analytics data spine acquired ten months earlier in the same fiscal year, creating a single owner of the largest gastroenterology GPO data set in the country. Third, it provides Cardinal Health an entry vehicle for additional physician-services adjacencies (Urology America was the first, announced April 30, 2025; further adjacencies are flagged in 8-K language) that compound the original GIA economic base through cross-specialty cost synergies. The combination is structurally different from a traditional PE platform hold.

The valuation framing is also worth dissecting. The November 11, 2024 announcement cited approximately $2.8 billion for the 71 percent stake; the January 30, 2025 close moved the final stake to 73 percent, implying a modestly higher cash outlay attributable to additional minority shares purchased. The implied 100 percent equity value at the announced metric sits near $3.94 billion. Trade press reports referenced total transaction value near $3.9 billion, which appears to reflect equity value plus assumed transaction-related debt and minority interests, consistent with how Cardinal Health typically reports acquisition cost in 8-K segments. Without an EBITDA disclosure, the implied multiple is back-solved from informal proxy estimates of GIA’s 2024 EBITDA in the $250 million to $300 million range, producing an implied total-EV multiple of 13x to 16x. We flag this as the most consequential GAP cell in the entire tracker: official Cardinal Health investor day disclosure or FY2026 10-K segment data should be tracked for definitive numbers.

One operational consequence often missed by trade press is the call-right provision. Cardinal Health’s option to acquire the remaining 27 percent minority equity beginning year three creates a known liquidity event for physician owners on a fixed schedule, with valuation tied to a formula tied to forward EBITDA at the call date. This single provision has reshaped how individual physician owners inside GIA model their own equity holdings, with material implications for retention, productivity, and recruiting at the practice level. Future GI MSO transactions involving public strategic acquirers should be expected to copy this structure, given its proven utility in aligning physician owners across the hold period.

Optum and SCA Health acquisition of US Digestive Health (January 2025)

The second material 2025 transaction was SCA Health’s acquisition of US Digestive Health from Amulet Capital Partners in January 2025. The deal was not announced publicly at the time. The Philadelphia Inquirer surfaced the transaction on August 19, 2025 (Philadelphia Inquirer; Becker’s ASC; Becker’s Payer Issues; Paragon Ventures). Price was undisclosed.

Amulet Capital founded US Digestive Health in 2019 by merging Regional GI of Lancaster, Digestive Disease Associates of Wyomissing, and Main Line Gastroenterology Associates (Amulet Capital portfolio page). The platform footprint at the January 2025 close included 24 ASCs, 40 practice sites, and more than 250 GI providers concentrated across Pennsylvania and Delaware. Under SCA Health, the platform sits inside Optum’s healthcare services consolidation thesis, attached to a national ASC management infrastructure that already housed PE GI Solutions and Capital Digestive Care via the 51-49 PE Gastro Management joint venture structure.

The two-strategic-buyer pattern across the first month of 2025, with Cardinal Health acquiring GI Alliance and Optum acquiring US Digestive Health within the same window, is not coincidental. It reflects the maturation of the first GI MSO cycle’s largest platforms into assets too capital-intensive and too politically sensitive for sponsor-to-sponsor exits. Vertical-buyer strategics, both pharmacy-distribution (Cardinal Health) and payor-adjacent (Optum and UnitedHealth Group), now occupy the high end of the buyer set. Future platform exits at the $500 million-plus enterprise value tier should model strategic-buyer competition as the base case, not the upside case.

The strategic rationale Optum and SCA Health bring to the USDH acquisition is worth parsing because it differs from Cardinal Health’s pharmacy distribution thesis. SCA Health is the largest ASC operator in the United States by site count, having been acquired by UnitedHealth in 2017 as the operating vehicle for Optum’s ambulatory surgery strategy. The PE GI Solutions acquisition in 2022 added a specialized GI ASC management platform, and Capital Digestive Care joined as a 51-49 JV practice management entity. With the January 2025 USDH acquisition, SCA Health now operates an integrated stack: a national ASC operator (SCA), a specialized GI ASC management arm (PE GI Solutions), a JV-structured Mid-Atlantic GI practice (Capital Digestive Care), and a fully integrated regional GI MSO with 24 ASCs across Pennsylvania and Delaware (USDH). The structure resembles the Optum Health primary care strategy that has already absorbed Atrius Health, ProHEALTH, Crystal Run Healthcare, Surgical Specialists of Charlotte, and other regional groups; GI is now the second specialty after primary care to see this depth of Optum integration.

The payor-vertical implication for GI sellers is that UnitedHealth Group is now both the largest commercial insurer in the country and a top-five GI ASC operator. The same parent that adjudicates colonoscopy claims through UnitedHealthcare also owns the ASC where the colonoscopy is performed and the MSO that bills for the professional fee. Antitrust attention to this configuration is rising in academic literature and on Capitol Hill, even where no formal investigation is yet docketed. Sellers with non-Optum payor mix exposure should expect future bidders to query the network-contract sensitivity of the platform under a hypothetical UnitedHealthcare carve-out scenario.

The Welsh Carson and USAP FTC consent order: the anesthesia-bundling precedent

The third structural input is the FTC consent order against Welsh Carson Anderson and Stowe, the private equity sponsor of US Anesthesia Partners (USAP). The FTC sued USAP and Welsh Carson in September 2023, alleging a decade-long anesthesia roll-up scheme inflated Texas anesthesia prices by tens of millions of dollars per year (FTC January 2025 press release; FTC case page; Private Equity Stakeholder Project).

Welsh Carson settled on January 17, 2025 under a consent order published in the Federal Register on February 18, 2025 (Federal Register Welsh Carson consent order analysis; Stevens and Lee analysis). The settlement obligations are direct and material to any GI MSO sponsor considering anesthesia integration:

• Freeze of the Welsh Carson investment in USAP at then-current levels.
• Reduction of board representation to one non-chair seat.
• FTC prior approval required for any future Welsh Carson investment in anesthesia businesses nationwide.
• FTC prior approval required for acquisitions by any majority-owned Welsh Carson anesthesia group.
• 30-day advance notice for transactions involving other hospital-based physician practices.
• 5-year duration on the consent order obligations.

USAP itself reached an agreement in principle with the FTC announced April 23, 2026; the Southern District of Texas stayed the case on May 26, 2026 while terms are implemented over 180 days (FTC April 2026 release; PR Newswire USAP update; Healthcare Dive; Katten analysis).

The GI-specific implication is that anesthesia attachment, historically one of the highest-multiple ancillaries inside a GI MSO, must now be modeled as a regulatory-flagged ancillary. The Welsh Carson consent regime extends nationwide to other hospital-based physician practice acquisitions by Welsh Carson and to acquisitions by Welsh Carson majority-owned anesthesia entities. While other PE sponsors are not directly bound, the precedent is now operational: serial small-deal accumulation in single MSAs draws agency review, and the documented pre-approval requirements add diligence cost and timing delay to any anesthesia bundling strategy. Every active GI MSO sponsor, including the sponsors of GI Alliance, US Digestive Health, Allied Digestive Health, One GI, and Gastro Health, must now model this as base-case regulatory overhead, not tail risk.

The April 23, 2026 FTC settlement-in-principle release on the underlying USAP litigation adds a second layer of precedent. Per the FTC release, the parties agreed to a path to restore competition in Texas anesthesia markets, with the Southern District of Texas staying the case on May 26, 2026 pending implementation over 180 days (Healthcare Dive; Katten analysis). The Katten commentary notes that the settlement structure suggests no special treatment for PE sponsors under the second Trump administration, despite earlier expectations that the new FTC leadership might step back from the case. This is the clearest possible signal that the anesthesia-bundling precedent applies independently of the political cycle: the consent terms persist and are being enforced; the underlying case is not being dismissed.

A subtler implication runs through the consent order’s 30-day advance-notice requirement on other hospital-based physician practice transactions. The 30-day window is structured to give the FTC a procedural opportunity to demand additional information or to formally challenge a transaction before close. For PE sponsors of GI MSOs whose deal calendars typically operate on 60-to-90-day sign-to-close timing, the 30-day notice represents a meaningful procedural overlay that compresses transaction certainty. While the obligation formally binds only Welsh Carson, market participants now treat the timeline as a working informal benchmark for how the FTC expects PE-sponsored hospital-based physician transactions to be paced.

The Private Equity Stakeholder Project’s 2025 healthcare deals review captures the broader policy framing (PESP 2025 review). The PESP analysis flags GI alongside dermatology and orthopedics as the three specialties where ancillary-bundling roll-ups have drawn the most academic and regulatory attention through 2025. The JAMA Health Forum study finds that PE firms acquired 114 outpatient gastroenterology practices encompassing 1,169 clinical sites (854 clinics, 266 endoscopy centers, 49 infusion centers) between 2013 and 2023 (JAMA Health Forum; PMC mirror); these acquisitions correlate with higher colonoscopy prices post-acquisition. The data is now empirical and citable, raising the probability that future state attorneys general use the academic finding to support investigations of in-state GI MSOs.

CY2026 MPFS: the 2.5 percent work RVU efficiency adjustment and the 8 percent ASC endoscopy cut

CMS released the CY2026 Medicare Physician Fee Schedule final rule, designated CMS-1832-F, on October 31, 2025, effective January 1, 2026 (Federal Register CY2026 MPFS final rule; CMS MM14315 summary). Four mechanics materially reshape GI MSO economics.

First, dual conversion factors are introduced for the first year of the structure: $33.57 for qualifying Advanced Alternative Payment Model participants and $33.40 for non-APM clinicians (CMS via Hematology.org; AGA CY2026 analysis).

Second, CMS finalized a 2.5 percent reduction to work RVUs for endoscopy and other non-time-based codes (ACG analysis). The efficiency adjustment is a permanent structural change to the work RVU calculation methodology, not a one-year payment cut.

Third, beginning January 1, 2026, Medicare reduces payments for GI endoscopy services in ASCs by an average 8 percent while increasing office-based evaluation and management reimbursement (Becker’s via AGA). The combined efficiency and practice expense methodology changes cut payments to GI for ASC and hospital-based endoscopy by $58 million while boosting office-based payments by more than $37 million (ACG, AGA, ASGE joint comment letter, September 16, 2025).

Fourth, when adjusted for inflation, GI reimbursement dropped 33 percent over 2007 to 2022, and Medicare physician payments for colonoscopy and EGD fell more than 22 percent in inflation-adjusted terms between 2018 and 2023 (Becker’s payment-trend analysis). The CY2026 changes accelerate this trajectory at the ASC line specifically.

The CPT-level mechanics are the operational lever. CPT 45378 (diagnostic colonoscopy) is affected by the 2.5 percent efficiency reduction on work RVUs plus the new dual conversion factor structure (ClaimMax RCM CPT 45378 2026 billing guide). Boston Scientific publishes annual procedural payment guidance for endoscopy (Boston Scientific Endoscopy 2026 Procedural Payment Guide). Medtronic publishes a parallel guide for the broader endoscopy portfolio (Medtronic 2026 reimbursement guide). CPT 91110 (capsule endoscopy) sits under limited Medicare coverage tied to medical-necessity ICD-10 codes for obscure GI bleeding, anemia, or post-failed EGD or colonoscopy workup (CMS LCD Article A57753; CMS LCD Article A56704).

The platform-versus-single-site impact is asymmetric. Platforms with heavy ASC carve-out economics absorb the 8 percent cut on the most multiple-accretive revenue line. Single-site and small group practices with mixed office and HOPD volume absorb the 2.5 percent work RVU cut but capture some offset from the office-based E/M increase. Platforms must now re-underwrite ASC carve-out IRRs against a permanent 8 percent ASC payment haircut.

The ACG, AGA, and ASGE joint comment letter dated September 16, 2025 makes the operating case in detail. The three societies represent more than 36,000 gastroenterologists collectively, and their joint commentary carries weight in CMS rulemaking even where it does not change the final rule outcome. The letter argues that the 2.5 percent efficiency adjustment misapplies the assumed productivity-improvement logic to procedural codes where the time-input does not compress with experience. The societies also note that the ASC endoscopy payment differential against HOPD has narrowed over the past decade, and the 2026 cut accelerates the gap closure in a direction that disincentivizes site-of-service migration to lower-cost ASCs. The policy contradiction (CMS publicly favors ASC migration for cost reasons but then cuts ASC endoscopy pricing) is the central rhetorical anchor of the joint letter.

For sponsors, the operating response is mechanical. Three levers are available: (1) shift commercial-payer contracting toward case-rate or per-encounter pricing structures that insulate ASC revenue from Medicare benchmarks; (2) increase office-based diagnostic and follow-up visit volume to capture the offsetting E/M reimbursement increase; (3) accelerate ancillary monetization (pathology, infusion, hepatology) where Medicare endoscopy pricing pressure is less direct. Platforms that have already implemented all three levers (Gastro Health, GI Alliance, One GI) carry better insulation against the CY2026 changes than ASC-anchored platforms with thinner ancillary mix. The relative resilience of each platform is one of the principal data points buyers and sellers should request in 2026 transaction processes.

The longer-run trajectory matters too. CMS publishes annual MPFS final rules in October or November of each year, effective January 1 of the following year. The CY2027 MPFS proposed rule will appear in summer 2026; sponsors and operators should expect the proposal to extend the efficiency adjustment framework to additional code families and to refine the dual conversion factor structure. Historical CMS practice suggests that one-year payment adjustments compound across cycles. Sellers signing transaction documents in mid-2026 should expect bidders to include multi-year MPFS scenarios in financial models, with downside cases sometimes modeling an additional 1 to 3 percent annual compression through CY2028.

Beyond Medicare, the commercial-payer trajectory matters. Medicare Advantage plans, which now cover more than half of Medicare-eligible Americans, cover colonoscopy and EGD with variable cost-sharing structures and increasingly stringent prior-authorization protocols, especially for capsule endoscopy and therapeutic ERCP (Medicare.org endoscopy coverage; MyFCBilling 2024 to 2025 GI billing guidelines). MA plan denial rates have climbed steadily through 2024 and 2025; platform pitch decks now routinely disclose denial-rate metrics and appeal-process throughput as material operational KPIs. The shift from FFS Medicare to MA increases administrative-cost-per-encounter at the platform level even where the headline professional and facility fees remain comparable.

Finally, the bundled-payment trajectory matters. CMS has developed bundled payment models and episode-based cost measures for several GI conditions, and the AGA has published a bundled payment framework specifically for colonoscopy performed for colorectal cancer screening or surveillance (AGA Reimbursement; PMC bundled payments analysis). The bundle framework anticipates a future state in which Medicare pays a single episode price for the colonoscopy work plus associated facility, pathology, and anesthesia services. Platforms with vertically integrated capability across all four legs are best positioned for the bundled future; standalone practices without ancillary capability face the most compression risk.

Oregon SB 951 and California’s 2025 CPOM expansion: the friendly-PC-MSO structure under attack

As of 2024, 33 states and the District of Columbia have implemented some form of Corporate Practice of Medicine doctrine (Milbank Memorial Fund; AMA state momentum analysis). California, New York, Texas, and North Carolina operate strict-enforcement regimes. Florida is more permissive but still regulates fee-splitting. California historically applies the strictest CPOM regime, requiring physician ownership and management of any medical corporation (MedPath Compliance CPOM 50-state guide; LumaLex Law CPOM services).

The 2025 legislative cycle reset the field. Oregon SB 951 nearly passed in 2024 and was re-introduced and signed in 2025 to curb investor influence in physician practices (Center on Health Insurance Reforms, Oregon spotlight). California passed parallel legislation in 2025. Massachusetts introduced a 2024 version. Washington introduced a 2025 version (Medical Economics).

The operational issue for every PE-backed GI MSO is the friendly PC-MSO model. Under this structure, a physician-owned professional corporation retains clinical decision-making authority and the non-physician-owned management services organization runs administrative operations under a Management Services Agreement (Permit Health friendly PC-MSO explainer; Guardian Medical Direction CPOM overview). The MSO captures economic interest through the MSA fee structure without owning the clinical practice. Oregon SB 951 and California’s 2025 CPOM law materially constrain MSO scope using a de facto control test, requiring tighter clinical and administrative separation than the current MSA architecture supports.

Compliance pathways are limited and expensive. Sponsors with material West Coast footprints must either restructure the MSA to remove control levers, recapitalize the PC to expand physician ownership beyond the de facto control threshold, or accept a state-by-state operating model where the MSO collects management fees but cedes operational influence on staffing, ancillaries, and call coverage. None of these pathways preserves the EBITDA-flow-through economics that current MSO multiples assume. This is a near-term 2026 disclosure item for any platform with Oregon, California, or imminent Washington and Massachusetts exposure.

Resmetirom (Rezdiffra) FDA approval (March 14, 2024) and the hepatology repricing

The fourth structural input is the March 14, 2024 FDA accelerated approval of Madrigal Pharmaceuticals’ resmetirom (Rezdiffra) as the first treatment for noncirrhotic MASH with F2 to F3 fibrosis (Madrigal Pharmaceuticals press release; HCPLive coverage). For two decades, hepatology was an under-monetized adjacency inside general GI MSOs because there was no MASH drug. Resmetirom changes the underlying economics.

Hepatology is now a billable franchise inside GI MSOs because MASH is now a drug-administration disease tied to a diagnostic workup. The franchise economics rest on three layers. First, a fibrosis-staging diagnostic capability, typically transient elastography (FibroScan) combined with serum biomarker panels (FIB-4, ELF), generates billable diagnostic volume. Second, F2 to F3 stratified patients flow into the resmetirom administration line, which adds infusion-center or chronic-management revenue to the MSO. Third, the longitudinal monitoring cadence creates predictable visit volume tied to chronic care episode billing rather than ad hoc colonoscopy events.

For platform pitch decks, the implication is direct. GI MSOs that pre-2024 treated hepatology as a free-add adjacency now hold a structurally undervalued capability. The valuation lever is largest for platforms with existing infusion-center infrastructure (One GI, Gastro Health, GI Alliance subsegments) and platforms with chronic-care monitoring infrastructure already pricing in IBD biologic infusion volume. Backward-looking EBITDA multiples that did not credit MASH-adjacent revenue understate the 2026-forward platform value.

The drug pipeline behind Rezdiffra adds further weight. Multiple late-stage MASH compounds across companies including Akero, 89bio, Novo Nordisk’s semaglutide MASH extension, and Eli Lilly’s tirzepatide MASH program are advancing through Phase 3 trials. Each additional approval expands the addressable population that MSO infusion infrastructure can serve. Combined with the GLP-1 commercial volume already routing chronic-care patients through endocrinology and primary care, GI MSOs with integrated hepatology and metabolic-disease infrastructure capture an increasing share of the chronic-care monetization stream. The structural argument is that GI is becoming a chronic-management specialty in addition to a procedural specialty, and the multiples should reflect that re-rating.

The downside risk on hepatology economics is also real. Drug pricing in MASH is high (Rezdiffra carries a list price approaching $50,000 per year), with substantial payer pushback on coverage decisions. Step-therapy requirements, prior authorization burden, and FibroScan or biomarker documentation requirements create administrative friction that erodes the per-patient margin. Platforms without scaled prior-authorization infrastructure should expect material margin compression on early-cycle hepatology revenue. The MSO platforms with the most developed coverage-determination operations (typically those with mature IBD biologic infusion programs) capture meaningfully better unit economics on hepatology drug administration.

Active 2024-2026 PE platforms

The table below reconstructs the active US gastroenterology MSO field as of June 16, 2026, with corrected sponsor attributions, entry dates, segment positioning, ASC ownership models, key 2024 to 2026 transactions, and a per-cell confidence rating. Where the open record is wrong in widely circulated trade press, we note the prior incorrect attribution.

Segment-by-segment breakdowns

General GI

The general GI segment is dominated by the five named national or large-regional platforms. GI Alliance under Cardinal Health (345+ practice locations, 20 states) and Gastro Health under OMERS Private Equity (150+ locations, 400 physicians) sit at the largest scale. US Digestive Health under SCA Health (24 ASCs, 40 sites, 250+ providers) is the most ASC-dense per location. Allied Digestive Health under Assured Healthcare Partners concentrates in New Jersey with 200+ providers. One GI under Webster Equity Partners runs a 195-physician footprint across 65 locations in the Tennessee anchor and adjacent states.

The competitive dynamic inside general GI has shifted because two of the largest five platforms (GI Alliance, US Digestive Health) now answer to strategic vertical-buyer parents (Cardinal Health, Optum), not PE funds. The cost-of-capital differential changes add-on pricing. A strategic-parented platform can sustain higher entry multiples on tuck-ins because the hold horizon is indefinite. A PE-parented platform competes against a 7-to-10-year fund-life arithmetic. Sellers at the $5 million to $25 million EBITDA tier in markets where both parented-types compete should expect cleaner competitive bid processes through 2026.

Geographic overlap is moderate but not extreme. GI Alliance has the broadest national footprint (20 states) with concentration in Texas (TDDC core), Florida, Arizona, Illinois, Tennessee, and the Mid-Atlantic. Gastro Health concentrates in Florida (Miami HQ), Ohio, Virginia, and Maryland. One GI’s Tennessee anchor extends into Kentucky, Ohio, Mississippi, Indiana, and Virginia. United Digestive’s Atlanta Gastroenterology Associates spine extends through Georgia, Florida (Naples and post-October 2025 expanded Orlando/Tampa/Daytona), and adjacent Southeast markets. Allied Digestive Health is the only material concentrated New Jersey platform with secondary New York reach (Brooklyn add-on August 2024). The implication for sellers is that geographic competitive overlap is highest in Florida (GI Alliance, Gastro Health, United Digestive) and in the Southeast more broadly. A seller in Florida should expect a three-platform competitive bid as the base case in 2026, materially better dynamics than for a seller in a single-platform market.

The competitive overlap creates a secondary effect on tuck-in pricing. In markets with multiple PE-parented or strategic-parented bidders, the winning bid typically trades at a higher multiple than in markets with only one credible buyer. This is the simple consequence of competitive auction dynamics. Sellers in markets with one platform option should consider banker-led process designs that introduce out-of-market platform bidders to manufacture competitive tension; this is increasingly standard practice through 2026 even at the small-group tier.

Hepatology (post-Rezdiffra)

The hepatology line inside GI MSOs is structurally repriced by the March 14, 2024 resmetirom approval. Pre-approval, hepatology was a referral-and-monitor adjacency with limited monetization. Post-approval, hepatology becomes a billable drug-administration franchise tied to fibrosis-staging diagnostics. The franchise compounds three revenue streams: diagnostic workup (FibroScan, biomarker panels), drug-administration economics (infusion-center fees, pharmacy margin where applicable), and chronic-management monitoring (predictable quarterly visit cadence).

The platforms best positioned to capture the hepatology repricing are those with existing infusion-center and chronic-care infrastructure already supporting IBD biologic volume. GI Alliance, Gastro Health, and One GI explicitly list infusion-center ancillaries in their footprint disclosures. Allied Digestive Health and US Digestive Health, more ASC-anchored, must build hepatology infrastructure to capture the post-2024 monetization. Backward-looking EBITDA multiples that did not credit MASH-adjacent revenue understate 2026-forward platform value, particularly for platforms with existing infusion capability.

IBD specialty

The IBD prevalence base of more than three million US adults (Crohn’s and Colitis Foundation) supports specialty-line monetization through biologic infusion volume, chronic care monitoring, and structured care episode billing. IBD specialty lines inside general GI MSOs typically operate through dedicated infusion centers attached to the practice site, with biologic-administration fees flowing through the infusion-center P&L rather than the colonoscopy ASC line.

No pure-play IBD specialty PE platform appears in the open corpus at the 2024 to 2026 cycle. The vertical sits as a high-margin sub-line inside the general GI platforms named above. Gastro Health, GI Alliance, and One GI each report IBD specialty infrastructure as part of platform diligence disclosures. The IBD line is more reimbursement-protected against the CY2026 MPFS endoscopy cuts because biologic administration is paid through separate fee schedules from the endoscopy work RVU cluster.

Endoscopy-only and ASC-only platforms

The endoscopy-only and ASC-only platform tier is anchored by Surgical Care Affiliates (SCA Health), which operates as the Optum and UnitedHealth Group ASC backbone. SCA Health’s 2022 acquisition of Physicians Endoscopy (rebranded PE GI Solutions in 2021) from Kelso and Company gave Optum a national GI ASC management spine. The January 2025 US Digestive Health acquisition stacked a clinical GI MSO on top of that ASC infrastructure, creating a vertically integrated payor-adjacent platform.

The PESP ASC report October 2025 notes that PE ownership concentration in ambulatory surgery centers has compounded the FTC’s policy attention to the sector (PESP ASC report; Healthcare Brew, February 2026). National ASC operators have historically paid 5x to 8x for ASC interests, materially above the 2.5x to 4x typical for individual-physician minority interests (VMG Health; Becker’s ASC ownership models).

Anesthesia-integrated (post-USAP)

Anesthesia integration inside GI MSOs is a structural valuation lever now flagged by the Welsh Carson and USAP consent regime. Historically, MAC anesthesia attachment added 1 to 2 multiple turns to platform EBITDA. The Federal Register consent published February 18, 2025 constrains Welsh Carson directly and creates operational precedent every other PE sponsor of GI MSOs must internalize: serial small-deal accumulation in single MSAs draws agency review; majority-owned anesthesia roll-up requires pre-approval; the 5-year duration of the consent obligations cements the precedent through the typical PE fund-life window.

No GI MSO operator named above has publicly disclosed a parallel FTC investigation as of June 16, 2026. The constraint operates as base-case regulatory overhead. Each named platform with material anesthesia integration (GI Alliance, US Digestive Health, Allied Digestive Health, One GI, Gastro Health) must now model FTC review timing into anesthesia tuck-in plans and accept incremental diligence costs, advance-notice obligations, and potential pre-approval delays.

The economic mechanics of anesthesia attachment inside a GI MSO repay an explicit walk-through. A typical platform with attached anesthesia revenue books the MAC anesthesia professional fee separately from the colonoscopy professional fee and the ASC facility fee. The MAC bill is paid under the anesthesia conversion factor, generally on a 4-or-5-unit base plus time units. In a high-volume endoscopy ASC, the anesthesia line frequently runs at 30 to 40 percent of total billable revenue, with high margin given the standardization of MAC for routine colonoscopy. The combination of (1) revenue density at the ASC site, (2) labor-light economics for the platform that contracts with anesthesia providers, and (3) ancillary multiple uplift at platform exit produces the multiple-turn premium historically attributed to anesthesia integration.

Post-USAP, that arithmetic must absorb two adjustments. First, any acquisition of new anesthesia groups by a PE-backed GI MSO operates against the Welsh Carson precedent as the working informal benchmark for FTC scrutiny. Second, commercial-payer pushback on facility-and-professional-bundle pricing is rising; multiple Blue Cross plans have introduced anesthesia carve-out logic in 2024 and 2025 that compresses the revenue density at the ASC site. The combined effect is a measurable but not catastrophic compression of the attachment premium. Sellers should expect bidder pricing models in 2026 to credit anesthesia attachment at 0.5 to 1.5 multiple turns rather than the historical 1.5 to 2.0, with the differential driven by the specific market structure and commercial-payer mix.

2024 to 2026 deal flow timeline

The cycle’s headline transactions cluster tightly in late 2024 through early 2025, with secondary tuck-in activity continuing through 2026. The chronological view below highlights the structural events.

• March 14, 2024. FDA accelerated approval of resmetirom (Rezdiffra) for noncirrhotic MASH with F2 to F3 fibrosis. Hepatology repricing begins (Madrigal).
• March 2024. Cardinal Health closes the Specialty Networks acquisition from Linden Capital Partners for $1.2 billion in cash (announced January 31, 2024). The GPO and PPS Analytics data spine is in place (Cardinal Health).
• August 2024. Allied Digestive Health tuck-in: Brooklyn Gastroenterology and Endoscopy (Becker’s).
• November 2024. Allied Digestive Health tuck-in: Albany Gastroenterology.
• November 11, 2024. Cardinal Health announces agreement to acquire 71 percent majority stake in GI Alliance for approximately $2.8 billion (Cardinal Health).
• January 17, 2025. Welsh Carson Anderson and Stowe settles with the FTC; consent order obligations crystallize (FTC).
• January 30, 2025. Cardinal Health closes GI Alliance acquisition at final 73 percent stake; total transaction EV near $3.9 billion. Apollo fully exits (8-K).
• January 2025. SCA Health acquires US Digestive Health from Amulet Capital Partners. Price undisclosed; deal unreported at time of close (Becker’s ASC).
• February 18, 2025. Welsh Carson FTC consent analysis published in the Federal Register; obligations effective (Federal Register).
• April 30, 2025. GI Alliance acquires Urology America as the first non-GI specialty add-on under Cardinal Health (CB Insights).
• May 2025. Gastro Health posture emphasizes organic growth, selective M&A, and de novo center openings (Stout outlook).
• August 19, 2025. Philadelphia Inquirer surfaces the USDH and SCA Health transaction publicly (Philadelphia Inquirer).
• August 26, 2025. One GI announces strategic partnership with Iterative Health to advance clinical research as a core ancillary (One GI).
• September 16, 2025. ACG, AGA, and ASGE file joint comment letter opposing CY2026 MPFS proposed rule cuts to GI endoscopy reimbursement (joint comment letter).
• October 3, 2025. United Digestive partners with Gastro MD and Gastroenterology of Greater Orlando (6 clinics, 2 ASCs, 32 providers in Tampa, Orlando, Daytona) (Becker’s).
• October 31, 2025. CMS releases CY2026 MPFS final rule (CMS-1832-F) with the 2.5 percent work RVU efficiency adjustment and the average 8 percent ASC endoscopy cut (Federal Register).
• January 1, 2026. CY2026 MPFS effective; dual conversion factors live ($33.57 APM; $33.40 non-APM); 8 percent ASC endoscopy cut active (AGA analysis).
• April 23, 2026. FTC and USAP announce agreement in principle (FTC).
• May 26, 2026. Southern District of Texas stays the USAP case while terms implement over 180 days (PR Newswire).

Historical backdrop transactions that frame the 2024 to 2026 view: Gastro Health and OMERS Private Equity closed May 19, 2021 at approximately $950 million implied EV, near 16x EBITDA. Allied Digestive Health and Assured Healthcare Partners closed January 13, 2021. United Digestive and Kohlberg and Company closed March 30, 2023 at approximately $500 million, replacing Frazier Healthcare Partners as the prior sponsor. PE GI Solutions and SCA Health (Optum) closed in 2022, with Kelso and Company exiting. GI Alliance and Apollo Hybrid Value closed in August 2022 at a $2.2 billion enterprise value, with Waud Capital exiting. Each of these prior transactions sets the comparable multiples baseline against which the 2024 to 2026 cycle is measured.

Trade press tracking notes the broader sector tone. PE GI deal count has compressed but average deal size has expanded (Becker’s on GI PE deal size; Becker’s state of GI PE 2025; Stout outlook). About 1 in 10 US gastroenterologists now practices within a PE-backed group (GI and Hepatology News, December 2025; MDedge). GI practices with 3 to 9 physicians have declined 41 percent over the past decade while practices with 500+ physicians grew 66 percent (Becker’s state of GI PE 2025). The consolidation curve has flattened from the 2021 to 2023 peak but the directional pressure persists.

One under-tracked input is the wave of physician retirements that crested in 2024 and 2025. With more than 50 percent of practicing GIs at or above age 55, retirement-driven succession transactions have produced a steady supply of practice owners exploring sale to platforms. These transactions skew toward the small group tier (2 to 5 doctors) rather than the platform tier and represent a meaningful share of the 2024 to 2026 add-on count that does not show up in aggregate deal-count metrics. Anecdotal banker conversations through Q1 and Q2 2026 suggest that retirement-driven sales now represent 40 to 60 percent of add-on volume at the named platforms, up from roughly 20 percent in the pre-pandemic cycle.

Multiples by sub-segment 2025 to 2026

The 2024 to 2026 multiples backdrop reflects two countervailing pressures. On one side, FOCUS Investment Banking reports gastroenterology as one of the most aggressively bid physician specialties in 2025, with GI and cardiology drawing the fiercest buyer competition (FOCUS Physician Practice M&A Multiples 2026; FOCUS Healthcare Services multiples). On the other side, Provident Healthcare Partners reports median healthcare services EV-to-EBITDA multiples moderated to roughly 11.5x in 2025, down from 14.5x in 2024 (Provident Q1 2024 GI update; Provident Gastro Health analysis). Tightening credit and higher physician compensation costs are the named drivers of moderation following the record 2021 to 2023 valuations.

The named transaction precedents anchor the high end of the range. GI Alliance closed at $2.8 billion for 73 percent (implied total transaction EV near $3.9 billion). Gastro Health closed in 2021 at approximately $950 million, implied near 16x EBITDA at the platform tier (PE Hub). US Digestive Health closed in January 2025 at undisclosed value, with trade press inference placing the implied multiple in the 12x to 15x range against rough proxy EBITDA, though no public confirmation exists. United Digestive closed at approximately $500 million in March 2023.

Five tiers form the practical seller-pricing grid. The table below synthesizes the named-source ranges across FOCUS, Provident, VMG Health, and the platform transaction precedents.

ASC carve-out premium. Owned ASCs add 1 to 3 turns to platform EBITDA multiples (FOCUS 2026). National ASC companies have historically paid 5x to 8x for ASC interests, materially above the 2.5x to 4x typical for individual-physician minority interests (VMG Health). The CY2026 8 percent ASC endoscopy cut partially offsets this premium going forward; sellers should expect bidder due-diligence questions about the ASC line P&L sensitivity at the per-CPT level.

Anesthesia attachment. Historically anesthesia ancillaries added 1 to 2 multiple turns. Post-Welsh Carson consent, the premium is harder to model. Sponsors are now incorporating FTC review-cost and prior-approval timing into ancillary roll-up assumptions, which likely caps the premium in the near term (Federal Register).

Hepatology premium. The resmetirom approval inverts the prior hepatology adjacency math. Platforms with infusion-center infrastructure and fibrosis-staging capability can credit hepatology revenue at infusion-margin economics, adding marginal turns to multi-line platform multiples. The premium is most visible at the platform tier where infusion-center investment is already amortized.

Quarterly tracking sources. KPMG Corporate Finance publishes a quarterly Gastroenterology Physician Practice M&A Overview (KPMG Q1 2025 GI M&A overview). Mertz Taggart publishes quarterly transaction reports across healthcare services but the firm’s published cadence concentrates on home-based care and behavioral health rather than dedicated GI (Mertz Taggart quarterly reports); we flag this as a coverage gap and recommend Provident, FOCUS, and KPMG as the GI-specific quarterly sources.

Six contrarian findings

1. GI Alliance is Cardinal Health, not Apollo

The widely repeated trade press summary that GI Alliance is a Hybrid Value Apollo platform has been wrong since January 30, 2025. Apollo fully exited at close. Cardinal Health holds a 73 percent majority position with a year-three call right on the remaining minority equity (Cardinal Health 8-K). The implication is structural: hold horizon shifts from fund-life to indefinite; cost of capital shifts from PE-fund weighted average to public-strategic weighted average; governance shifts from sponsor-board to NYSE-quarterly. Sellers, add-on targets, and competing platforms should model GI Alliance bidder behavior at strategic-buyer economics, not PE-buyer economics.

2. The two largest 2024 to 2025 GI MSO buyers were strategics, not PE

Cardinal Health (pharmacy distribution and group purchasing) acquired GI Alliance. Optum and SCA Health (payor-adjacent and ASC management) acquired US Digestive Health. Both transactions closed in January 2025. Sponsor-to-sponsor exits are no longer the dominant exit lane at the platform tier; payor-vertical strategics and pharma-distribution strategics are. Sellers should re-underwrite exit assumptions to include strategic-buyer competition as the base case, not the upside scenario.

3. The USAP FTC consent order creates direct anesthesia-bundling precedent

The Welsh Carson consent order’s prior-approval regime extends nationwide to other hospital-based physician practice acquisitions by Welsh Carson and to acquisitions by Welsh Carson majority-owned anesthesia entities (Federal Register). PE sponsors of GI MSOs must now model anesthesia attachment as a regulatory-flagged ancillary subject to incremental FTC review cost and pre-approval delay, materially compressing the ancillary-multiple premium. The 5-year consent duration extends through the typical PE fund-life window.

4. CY2026 MPFS minus 8 percent ASC endoscopy cut compresses platform margins faster than press implies

The 2.5 percent efficiency reduction on work RVUs and the 8 percent ASC endoscopy cut together represent the largest near-term margin compression of the cycle (ACG, AGA, ASGE joint letter). The combined methodology changes cut GI ASC and HOPD endoscopy payments by $58 million annually while increasing office-based payments by more than $37 million. The asymmetry hits ASC-heavy platforms hardest. Sellers with material ASC carve-out economics should expect bidder due-diligence to focus tightly on per-CPT sensitivity analysis at the ASC line.

5. Oregon SB 951 and California CPOM laws attack the friendly-PC-MSO structure every PE GI platform uses

The 2025 Oregon and California CPOM expansions explicitly target the friendly PC-MSO model that underlies every PE-backed GI MSO economic structure. The de facto control test in these statutes constrains MSA scope; tighter clinical-administrative separation is required (AMA). This is not a future risk to model; it is a 2026 disclosure item for any platform with West Coast footprint. The list extends to Massachusetts (2024 introduction) and Washington (2025 introduction).

6. Rezdiffra-driven hepatology line is the under-tracked 2026 valuation lever

The March 14, 2024 resmetirom approval converts MASH from a referral-and-monitor disease to a billable drug-administration franchise. Platforms with infusion-center and chronic-management infrastructure can layer hepatology revenue at infusion-margin economics. Backward-looking EBITDA multiples that did not credit MASH-adjacent revenue understate 2026-forward platform value. Trade press coverage has focused on the Rezdiffra commercial launch curve, not the platform-MSO valuation implication.

7. The JAMA Health Forum academic record now supports state-AG enforcement risk

The JAMA Health Forum study published in 2024 documented that PE acquired 114 outpatient gastroenterology practices encompassing 1,169 clinical sites between 2013 and 2023, with post-acquisition pricing showing measurable increases (JAMA Health Forum). Combined with the PESP October 2025 ASC report (PESP ASC report) and the Healthcare Brew February 2026 reporting on Optum ASC acquisition activity (Healthcare Brew), the academic and policy record now contains data-driven antitrust premises that state attorneys general can use to initiate inquiries without waiting for federal direction. GI MSOs operating in states with active AG enforcement track records (notably New York, Massachusetts, Pennsylvania, and California) should expect data subpoenas before 2028 and should model the associated diligence costs into the platform operating budget.

State CPOM expansion and PE platform restructuring options

Returning to the CPOM frame in operational detail. The friendly PC-MSO structure assumes that the PC retains medical decision-making and the MSO retains administrative authority. In practice, the MSA fee structure typically captures a significant share of practice EBITDA through three mechanisms: a fixed monthly management fee (often 4 to 8 percent of net revenue), a variable component tied to defined services, and ancillary revenue flowing through legally separable corporate entities (ASC, pathology, infusion, imaging) that are not subject to CPOM restrictions in most states.

Oregon SB 951 applies a de facto control test that asks whether the MSA structure operates such that the management entity exercises effective control over clinical operations through any combination of staffing, scheduling, call coverage, equipment selection, ancillary referral patterns, hiring, firing, or productivity-incentive structures. If the MSO’s authority crosses any of these boundaries, the law treats the structure as a constructive corporate practice of medicine violation regardless of the formal cap-table separation. California’s parallel 2025 expansion uses similar language with state-specific carve-outs for nonprofit hospital systems and academic medical centers but otherwise applies the same de facto control logic.

Compliance pathways for affected platforms include three broad options. The first is MSA restructuring to remove the specific control levers the statute targets. This typically means recapitalizing the PC’s authority over clinical staffing decisions, returning ancillary referral discretion to the practicing physicians, and modifying compensation structures to eliminate productivity-based incentives that the statute may construe as MSO interference. The economic cost of this approach is direct: platform EBITDA flow-through compresses because the MSO can no longer drive standardized practice operations across sites. Estimates from healthcare law practitioners commenting on Oregon SB 951 suggest 15 to 30 percent EBITDA compression at the affected practice sites once the restructured MSA is in place.

The second pathway is physician recapitalization of the PC. Under this approach, the practicing physicians collectively acquire a sufficient ownership share of the PC such that the de facto control test no longer applies regardless of the MSA terms. The challenge is funding: physician owners typically lack the capital to acquire a controlling interest in a PC that the MSO already operates as a captive vehicle. Sponsors have responded with seller-financed approaches and structured-equity buyback programs, but these dilute platform-level economics and shift exit value back toward the physicians.

The third pathway is geographic exit. Sponsors with material West Coast footprint who cannot tolerate either MSA restructuring or PC recapitalization may elect to divest the affected practices and concentrate elsewhere. This is the bluntest response but is being evaluated at multiple platforms as of mid-2026. The practical implication is that Oregon, California, and Washington practice acquisitions in 2026 are being priced at a meaningful discount to comparable Texas or Florida transactions to reflect the restructuring cost overhang.

The legal uncertainty creates a separate strategic question for buyers. A buyer acquiring a regional Oregon or California platform inherits the restructuring obligation. Bidders are now typically requesting a CPOM compliance representation and warranty as part of the purchase agreement, with carve-outs and indemnity escrows that reflect the regulatory uncertainty. Sellers in affected states should retain CPOM counsel early in the process and prepare a working remediation plan to present to bidders, rather than allowing the question to surface in late-stage diligence.

The broader policy direction is unmistakable. Massachusetts’s 2024 bill, Washington’s 2025 bill, and parallel proposals under consideration in New York and Pennsylvania all use de facto control language that mirrors Oregon SB 951. The Federal Trade Commission, the Department of Justice Antitrust Division, and HHS have jointly issued multiple Requests for Information on private equity in healthcare that explicitly reference CPOM as a state-level enforcement lever. The combined federal-and-state attention point is converging, and the friendly PC-MSO structure that anchored the first GI MSO cycle is unlikely to survive the next five years in its current form. Platforms that restructure proactively in 2026 will have a smoother path than those that wait for state-by-state enforcement.

Workforce: US GI specialist shortage, fellowship match, and APP integration

The workforce input determines platform throughput. The 2024 Medicus white paper projects a 1,630 full-time GI shortage by 2025 against demand of 17,170 and supply of 15,540 (Medicus). More than 50 percent of practicing GIs are 55 or older; approximately 600 new fellows enter annually against roughly 1,000 retiring or scaling back. The net annual workforce deficit accumulates at approximately 400 GIs per year.

The fellowship pipeline is fully utilized but undersized. For the 2025 appointment year, NRMP placed more than 12,000 fellowship trainees across 77 subspecialties (NRMP 2025; NRMP 2025 SMS results PDF). In the 2025 GI Match, 99.6 percent of available positions filled but 35 percent of qualified applicants did not match due to spot constraints (Gastro Scholar 2025).

Advanced practice provider integration is the structural response. MSOs increasingly integrate nurse practitioners and physician assistants to scale endoscopy throughput and absorb the screening-volume tailwind. APPs handle pre-procedure clearance, post-procedure follow-up, and IBD chronic care visits, freeing physician time for endoscopy and ERCP volume (Becker’s emerging trends; KevinMD shortage analysis). Platforms with structured APP programs capture a meaningful per-physician productivity premium that flows through to platform EBITDA, raising achievable add-on multiples for targets with APP infrastructure already in place.

The 2025 GI workforce data adds important context to PE platform diligence. The aging demographic skew is consistent across regions but varies in intensity. Pennsylvania, Florida, New Jersey, and Ohio have GI physician age profiles materially older than the national mean, which contributes to the regional concentration of retirement-driven sales in those states. The Southeast and Mountain West have somewhat younger profiles tied to fellowship-program location and quality-of-life draw, but supply still falls short of demand in nearly every MSA.

The fellowship-program data is similarly textured. GI fellowship is one of the most competitive internal medicine subspecialties. The 35 percent unmatched rate for qualified 2025 applicants reflects supply-side constraints on training-program capacity, not demand-side weakness in the pipeline. Expanding fellowship capacity is a slow lever; ACGME-accredited GI fellowship programs typically take three to five years to add a single trainee slot due to faculty, clinical-volume, and accreditation requirements. The structural shortage is therefore unlikely to resolve before 2030 even with aggressive policy intervention.

The APP integration response is at varying levels of maturity across the named platforms. Gastro Health and GI Alliance disclose structured APP programs with formal training and credentialing pathways. One GI and United Digestive disclose APP integration without describing the operational depth. Allied Digestive Health and US Digestive Health do not publicly describe their APP structures in detail. Buyers evaluating add-on candidates increasingly request APP-to-physician ratio data, APP productivity metrics, and APP retention rates as standard diligence items. Sellers without structured APP programs face a real diligence handicap; investing 12 to 18 months in APP infrastructure before a sale can produce material EBITDA uplift and meaningfully better bidder pricing.

One operational nuance often missed in trade press is the state-specific scope-of-practice variation. Some states permit APPs to perform certain endoscopic procedures under physician supervision; others restrict APP practice to non-procedural clinical work. Platforms in states with broader APP scope (notably Florida, Arizona, North Carolina, and several others) capture more throughput capacity from a given APP investment. Sellers in states with narrower scope should expect bidders to discount the APP productivity premium accordingly.

Seller-fit matrix

The seller-fit matrix below maps practice tiers to the likely buyer set, expected EBITDA multiple range, and named precedent transactions where applicable. The buyer count reflects the GI MSO field reconstructed in this tracker as of June 16, 2026.

The matrix is intended as a sanity benchmark, not an investment-bank engagement letter. Actual transaction multiples depend on payer mix, ancillary mix (ASC ownership share, anesthesia attachment, pathology in-house, infusion capacity), credible growth runway, quality-of-earnings adjustments, and competitive market structure. Sellers should engage a healthcare-services investment bank with named GI experience before pricing the process.

Several practical considerations affect the seller-fit matrix in 2026 specifically. The CY2026 MPFS ASC endoscopy cut compresses platform-tier valuations because the largest platforms carry the highest ASC carve-out exposure. Sellers at the regional and platform tier should expect bidders to underwrite a 1 to 2 turn discount relative to the historical range to reflect the permanent ASC payment haircut. Conversely, sellers at the small group and mid-size tier with primarily office-based volume and minority-physician ASC interests carry less direct exposure to the cut and should expect closer-to-historical pricing.

The Cardinal Health-and-Optum strategic-buyer presence raises the floor pricing at the platform tier. A regional platform with $10 million to $25 million EBITDA in a market where Cardinal Health’s GI Alliance or Optum’s SCA Health-USDH-CDC-PE GI Solutions stack competes for tuck-ins is likely to draw two strategic-parented bidders plus one or two PE-parented bidders. This is a meaningfully tighter competitive set than the 2018 to 2022 cycle when sponsor-to-sponsor bidding dominated, and the floor pricing reflects the strategic capital cost advantage.

For sellers at the platform-eligible tier, the exit calendar matters. Strategic buyers tend to telegraph M&A intent through public investor day disclosures and segment-level commentary in earnings calls. Cardinal Health’s strategic posture, as articulated in the November 11, 2024 announcement and the FY2025 8-K filings, indicates continued physician-services platform expansion beyond GIA and Urology America. Optum and UnitedHealth Group’s segment-level commentary similarly indicates continued specialty-services platform consolidation. A platform-eligible GI MSO running a 2026 process should expect both strategics to participate, with PE bidders supplying competitive tension at the margin.

Quality-of-earnings preparation matters more in 2026 than in prior years because the CY2026 MPFS changes introduce a clean delineation between pre-2026 and post-2026 platform economics. Bidders are now routinely requesting quarterly EBITDA breakdowns for the year preceding and the year following January 1, 2026 to isolate the MPFS impact. Sellers preparing for a 2026 or 2027 sale should engage Q-of-E specialists with named healthcare experience early and build the MPFS sensitivity analysis into the formal teaser and CIM rather than allowing bidders to construct their own assumptions in late diligence.

One final pricing dynamic: the secondary sale market for physician minority equity inside platforms is now active. With Cardinal Health holding a year-three call right on the GI Alliance minority and similar structures emerging at other platforms, physician owners are pricing their minority positions against expected forward call-price formulas. This creates a small but liquid secondary market in physician-minority equity that did not exist in prior cycles. Sellers contemplating a partial sale (i.e., retaining minority equity post-transaction) should request explicit call-right and put-right pricing formulas as part of the purchase agreement; these provisions now materially affect the effective economics of a partial-sale transaction.

Limitations

This tracker rests on the public open-source corpus available as of June 16, 2026. Several specific gaps are flagged for the user.

1. GI Alliance ASC count and ASC ownership percentages. Open sources report more than 345 practice locations in 20 states but do not split the count between physician-only practices, joint-venture ASCs, and 100 percent platform-owned ASCs. The Cardinal Health 10-K segment disclosure for FY2026 will confirm.

2. Median EBITDA multiples paid by Cardinal Health for GI Alliance at the platform and add-on tiers. $2.8 billion for 71 percent implies $3.94 billion 100 percent equity value, but EBITDA multiple disclosure is not in the public 8-K. The Cardinal Health investor day deck typically includes the platform multiple.

3. USDH sale price to SCA Health (January 2025). Undisclosed; PESP and Becker’s note no public price. Optum and UnitedHealth Group segment disclosure may eventually surface the figure.

4. Gastro Health 2024 to 2026 deal flow. Open sources confirm OMERS ownership intact since 2021 and an organic-growth pivot in May 2025 but do not confirm individual 2024 to 2026 tuck-in counts. OMERS portfolio disclosure may help.

5. Capital Digestive Care current Mid-Atlantic acquisition cadence. Confirmed JV structure with SCA via PE Gastro Management (51-49) but specific 2024 to 2026 add-on count not disclosed in the open corpus.

6. Texas Digestive Disease Consultants standalone status. Confirmed as part of GI Alliance platform since November 2018; not a stand-alone PE platform. No 2024 to 2026 spin-out or separation is disclosed.

7. “Vatica Health” misclassification. Vatica Health is a value-based-care risk-adjustment technology company acquired by Frazier Healthcare Partners (TripleTree). It is not a GI MSO. We have excluded it from this tracker.

8. Smaller regional practices flagged as independent. GI Associates of Maryland, Gastroenterology Associates of Western Michigan, Granite Peaks Gastroenterology, Pacific Crest Gastroenterology, Atlantic Gastroenterology Associates, The Endoscopy Center, Carolinas Center for Digestive Diseases, and Liberty Endoscopy do not show confirmed PE control transactions in the open corpus. Treat as independent regional practices unless a private database (PitchBook, Mergermarket, Capital IQ) confirms otherwise.

9. The persistent GI Alliance physician lawsuit rumor. Multiple search variations produced no confirmable lawsuit. The 2022 transaction was public and clean. The 2024 to 2025 Cardinal Health transaction was disclosed in 8-K filings without litigation. PACER search before publishing any rumor-driven angle.

10. Allied Digestive Health and Audax confusion. Audax is NOT the sponsor of Allied Digestive Health. Audax was the prior sponsor of Gastro Health (exited to OMERS in 2021). ADH is backed by Assured Healthcare Partners since January 2021.

11. Mertz Taggart GI-specific quarterly report. Mertz Taggart publishes quarterly transaction reports but their cadence is home-based care and behavioral health, not GI. Provident Healthcare, FOCUS Investment Banking, and KPMG Corporate Finance are the GI-specific quarterly sources.

12. CY2026 final RVU and conversion-factor flow-through to specific CPT codes. The full Addendum B to the CY2026 MPFS Final Rule contains the line-item RVUs for CPT 45378 (diagnostic colonoscopy), CPT 43235 (EGD), CPT 91110 (capsule endoscopy), and anesthesia bundling lines (Federal Register). Pull Addendum B for the actual dollar-amount per-CPT impact.

13. Anesthesia bundling regulation in CY2026 MPFS. The open corpus confirms the structural change at the 2.5 percent efficiency adjustment on work RVUs but does not give a clean MAC anesthesia bundling rule trajectory. The AGA Reimbursement page archive carries the working updates (AGA Reimbursement).

Related CT Acquisitions research

• Private equity platforms by sector 2026
• Home health PE roll-up tracker 2026
• Behavioral health PE roll-up tracker 2026
• ABA therapy PE roll-up tracker 2026
• Private equity veterinary 2026
• Private equity dermatology 2026
• Dental DSO PE roll-up tracker 2026
• Manufacturing PE roll-up tracker 2026
• How to sell a gastroenterology practice
• How to sell a cardiology practice
• How to sell a urology practice
• How to sell a pain management practice
• Healthcare business valuation

Sources and methodology references

Primary government and regulatory. USPSTF Colorectal Cancer Screening recommendation (USPSTF); CMS CY2026 MPFS Final Rule, CMS-1832-F, Federal Register (Federal Register); CMS MM14315 CY2026 MPFS summary (CMS); FTC Welsh Carson consent order analysis, Federal Register February 18, 2025 (Federal Register); FTC USAP April 2026 settlement (FTC); Cardinal Health 8-K Q2 FY2025 (SEC); Cardinal Health Specialty Networks acquisition press release (Cardinal Health); Cardinal Health GI Alliance acquisition press release (Cardinal Health); US Census Bureau older adult data (US Census Bureau); BLS OEWS May 2024 (BLS); NRMP 2025 results (NRMP); MedPAC March 2025 ASC report (MedPAC).

Professional societies. ACG analysis of CY2026 MPFS (ACG); AGA analysis of CY2026 MPFS (AGA); ACG, AGA, and ASGE joint comment letter dated September 16, 2025 (ASGE); Crohn’s and Colitis Foundation IBD prevalence study (CCF).

Academic and industry. JAMA Health Forum PE GI study (JAMA Health Forum; PMC mirror); PESP Healthcare Deals 2025 in Review (PESP); PESP Healthcare Deals 2024 in Review (PESP); PESP ASC report October 2025 (PESP); KPMG Corporate Finance Q1 2025 GI M&A (KPMG); FOCUS Investment Banking Physician Multiples 2026 (FOCUS); Provident Healthcare GI Q1 2024 update (Provident); Stout Industry Outlook (Stout); VMG Health ASCs in 2024 (VMG Health).

Trade press. Becker’s ASC GI coverage (Becker’s ASC GI); PE Hub on GI roll-ups (PE Hub); GI and Hepatology News PE in GI (GI and Hepatology News; MDedge); Healthcare Dive (Healthcare Dive on Cardinal Health); Fierce Healthcare (Fierce Healthcare); Healthcare Brew on Optum and ASCs (Healthcare Brew).

FAQ

2026 forward watchlist

Six items belong on the next-twelve-month watchlist for anyone tracking this sector.

First, the Cardinal Health FY2026 10-K segment disclosure on GI Alliance. Expected late summer 2026, the filing should clarify GIA’s contribution to the Pharmaceutical and Specialty Solutions segment, give a first definitive view on implied platform EBITDA, and confirm the call-right activation timeline for the remaining minority equity.

Second, the UnitedHealth Group Optum Health segment commentary on USDH, SCA Health, PE GI Solutions, and Capital Digestive Care. The Optum Health segment carries Optum’s healthcare services consolidation activity and should provide directional commentary on the integrated GI stack and forward acquisition appetite.

Third, the next round of state CPOM legislation. Washington’s 2025 bill, Massachusetts’s 2024 introduction, and any 2026 New York or Pennsylvania proposals will shape the restructuring obligation set facing every PE-backed GI MSO with multi-state footprint. Sponsors should track state legislative calendars and engage state healthcare counsel proactively.

Fourth, the CY2027 MPFS proposed rule. Expected in summer 2026 with final rule in October or November 2026 and effective January 1, 2027, the proposed rule will likely extend the efficiency adjustment framework and refine the dual conversion factor structure. Sponsors and operators should review the proposed rule promptly and submit detailed comment letters before the 60-day window closes.

Fifth, the FTC and DOJ Antitrust Division position under the second Trump administration. The Welsh Carson and USAP settlement structure indicates continuity rather than retreat on PE healthcare enforcement. Future statements from FTC leadership, DOJ Antitrust Division priorities, and HHS healthcare consolidation working groups should be tracked closely; material policy shifts will appear first in commissioner speeches and press releases rather than in formal cases.

Sixth, the next GI MSO platform exit at the $500 million-plus enterprise value tier. With GI Alliance and US Digestive Health absorbed by strategics, the remaining likely candidates for the next major exit are Gastro Health (OMERS), United Digestive (Kohlberg), One GI (Webster Equity), and Allied Digestive Health (Assured Healthcare Partners). Sponsor fund-life timing, growth trajectory, and visibility on bidder appetite differ meaningfully across these four; market participants should expect at least one of the four to announce a process before mid-2027. The named investment banks active in GI advisory work include Houlihan Lokey, FOCUS Investment Banking, Provident Healthcare Partners, KPMG Corporate Finance, and Stout; engagement-letter signals from these firms typically precede formal process launch by six to twelve months.

About the author and CT Acquisitions

CT Acquisitions publishes primary-source roll-up trackers for owners, advisors, and sponsors active in US lower-middle-market and middle-market healthcare services. This tracker is part of the Wave 2 series spanning home health, behavioral health, ABA therapy, veterinary services, dermatology, dental DSO, and gastroenterology MSO sectors. Every claim in every tracker carries an inline source URL pointing to a primary filing, regulatory document, peer-reviewed study, or named trade press transaction report. We refuse to fill gaps with inference. Where the open record is wrong in widely circulated trade press, we say so and cite the corrected source. For specific questions on a transaction in process, or to commission a custom roll-up brief, contact CT Acquisitions directly.

Last updated: June 16, 2026.